TSS
ADAP

Two Sigma Securities’s Adaptimmune Therapeutics ADAP Stock Holding History

Two Sigma Securities’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13,386
Closed -$89K – 2635
2017
Q4 		$89K Buy
+13,386
New +$103K ﹤0.01% 1465

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Two Sigma Securities's ADAP Position: Q1 2018 in Review

Two Sigma Securities sold out of Adaptimmune Therapeutics (ADAP) in Q1 2018, closing a stake of 13,386 shares — an estimated $89K sold.

Two Sigma Securities first reported a position in ADAP in Q4 2017 and held it in 1 quarter. The position peaked at $89K in Q4 2017. 76 funds tracked by Wall St. Rank hold ADAP as of Q1 2018.

  • Two Sigma Securities reported no remaining Adaptimmune Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Two Sigma Securities sold 13,386 Adaptimmune Therapeutics shares in Q1 2018, an estimated $89K.
  • Two Sigma Securities first reported a position in Adaptimmune Therapeutics in Q4 2017 and held it in 1 quarter.
  • Two Sigma Securities's Adaptimmune Therapeutics position peaked at $89K in Q4 2017.
  • 76 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2018.

Based on Two Sigma Securities's 13F filing for Q1 2018, filed 15 May 2018.